Skip to main content

Remote Job Finders (RJF)

More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the company is leveraging its unprecedented success in obesity to support young biotechs.

More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds

EY’s 2025 Biotech Beyond Borders report provides a sobering snapshot of the industry’s financial health, with more and more companies facing cash runways of less than one year. The analyst firm’s leaders urge a return to basics for biotech.
Scroll to top